Skip to main content

搜索 Proteome Profiler 固相抗体芯片

Quick Spots Image Analysis Software

R&D Systems® now offers Quick Spots image analysis software designed specifically for your Proteome Profiler Arrays.

No more laborious set-up of templates in other imaging software, Quick Spots contains preloaded templates for each Proteome Profiler array. It knows where your results should be and provides the data in less time and with less work.

Webinar Icon

Webinar: Understanding Immunosuppressive Myeloid Cells and Immunotherapy

Advanced Prostate Cancer (PCa) can progress to lethal metastatic castration-resistant prostate cancer (mCRPC), even when treated with androgen deprivation therapy.  Although immune checkpoint blockade has revolutionized the way cancer is treated, it is less effective in this context. Watch this video to see how Proteome Profiler antibody arrays were used by Dr. Xin Lu and his research team as they addressed this challenge. See how they demonstrated increased synergistic antitumor efficacy when an immune checkpoint blockade cocktail (CTLA-4 and PD1) is used in combination with PI3-kinase signaling pathway inhibitors. Find out about the role that myeloid-derived suppressor cells play in aggressive cancer.

Webinar Icon

Profiling Changes in Receptor Tyrosine Kinase Phosphorylation Using Antibody

Watch this video to learn about the principle of the Proteome Profiler antibody array. See how assays are run with this step-by-step detailed description of the method.

Proteome Profiler Antibody Array

Antibody Array Principle


  1. Capture antibodies are spotted in duplicate on the nitrocellulose membrane.
  2. Spotted membrane arrays are incubated in a single lysate.
  3. Target analytes are captured by the capture antibody.
  4. Target analytes are detected using a biotinylated or horseradish peroxidase (HRP)-conjugated detection antibody.
  5. Biotinylated detection antibodies are reacted with streptavidin HRP.
  6. Membranes are incubated in a chemiluminescence reagent that produces a light signal proportional to the amount of antibody-target analyte complexes formed.
  7. Data is visualized using standard western blotting methods such as film or digital cameras.

Luminex® is a trademark of Luminex Corporation.